Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catechol-based polyphenols are a broad class of secondary plant metabolites defined by the presence of a catechol functional group, which consists of a benzene ring with two adjacent hydroxyl groups [1, 12]. Found in abundance in dietary sources such as tea, fruits, and vegetables, these compounds include well-known flavonoids like quercetin and green tea catechins like epigallocatechin gallate (EGCG) [3, 6]. Biologically, they function as pleiotropic ligands that interact with multiple molecular targets, including signaling proteins (e.g., Keap1), metabolic enzymes (e.g., COMT), and structural proteins (e.g., beta-actin), rather than acting as a single receptor or enzyme [1, 10]. These molecules are prized for their antioxidant, anti-inflammatory, and neuroprotective properties, though their therapeutic efficacy is often limited by poor metabolic stability and low systemic bioavailability [6, 15]. In the context of drug development, they are frequently explored as scaffolds for designing inhibitors of protein aggregation or as modulators of oxidative stress pathways. Because 'catechol-based polyphenols' refers to a chemical class of ligands rather than a specific biological target molecule, the term is categorized as incorrect in the context of identifying a single therapeutic target [2, 12].
Catechol-based polyphenols primarily act by scavenging reactive oxygen species (ROS) and chelating transition metal ions like iron and copper to prevent oxidative damage [3, 11, 16]. They also undergo oxidation to form electrophilic o-quinones that covalently modify protein cysteine residues, such as those on the Keap1 scaffold protein, thereby activating cytoprotective pathways like Nrf2 [1]. Furthermore, they can inhibit specific enzymes including catechol-O-methyltransferase (COMT), matrix metalloproteinases (MMPs), and prevent protein aggregation, such as alpha-synuclein [1, 12].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Catechol-based polyphenols.